Lupus Nephritis - Pipeline Review, H2 2016

Date: September 28, 2016
Pages: 142
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: LBC9371C5F0EN
Leaflet:

Download PDF Leaflet

Lupus Nephritis - Pipeline Review, H2 2016
Lupus Nephritis - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Lupus Nephritis - Pipeline Review, H2 2016’, provides an overview of the Lupus Nephritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lupus Nephritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Lupus Nephritis
  • The report reviews pipeline therapeutics for Lupus Nephritis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Lupus Nephritis therapeutics and enlists all their major and minor projects
  • The report assesses Lupus Nephritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Lupus Nephritis
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Lupus Nephritis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lupus Nephritis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Lupus Nephritis Overview
Therapeutics Development
Pipeline Products for Lupus Nephritis - Overview
Pipeline Products for Lupus Nephritis - Comparative Analysis
Lupus Nephritis - Therapeutics under Development by Companies
Lupus Nephritis - Therapeutics under Investigation by Universities/Institutes
Lupus Nephritis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Lupus Nephritis - Products under Development by Companies
Lupus Nephritis - Products under Investigation by Universities/Institutes
Lupus Nephritis - Companies Involved in Therapeutics Development
AbbVie Inc
Asahi Kasei Pharma Corp.
Astellas Pharma Inc.
Aurinia Pharmaceuticals Inc
Azano Pharmaceuticals Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Deltanoid Pharmaceuticals Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
HanAll Biopharma Co., Ltd.
Invion Limited
KPI Therapeutics, Inc.
MedImmune, LLC
Omeros Corporation
Ra Pharmaceuticals, Inc.
Resolve Therapeutics, LLC
Takeda Pharmaceutical Company Limited
TxCell SA
Lupus Nephritis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abatacept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
anifrolumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-655064 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986147 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dalazatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENTX-DN - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HL-161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INV-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ixazomib citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mizoribine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Lupus Nephritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
obinutuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-721 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-Dex - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RA-101495 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-5461111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RSLV-145 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Autoimmune Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Complement C5 for Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome and Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
venetoclax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
voclosporin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Y-175L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lupus Nephritis - Dormant Projects
Lupus Nephritis - Discontinued Products
Lupus Nephritis - Product Development Milestones
Featured News & Press Releases
Aug 15, 2016: Aurinia Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase IIB AURA-LV Study in Lupus Nephritis
Jun 28, 2016: Aurinia Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis (LN)
Jun 10, 2016: Alliance for Children Therapeutics Presents Dalazatide Data Demonstrating Positive Response in Lupus
May 23, 2016: KPI Therapeutics to Present Updated Dalazatide Study Data in Lupus
May 12, 2016: Aurinia Announces Presentations at the European Renal Association - European Dialysis and Transplant Association Meeting
May 09, 2016: Aurinia Initiates First Clinical Study of Voclosporin for Japan
Apr 20, 2016: Patient Dosing Initiated for OMS721 Phase 2 Program in Renal Diseases
Mar 29, 2016: Aurinia Announces Result from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis - Study to Continue as Planned
Mar 02, 2016: Aurina Receives FDA Fast Track Designation for Voclosporin for the Treatment of Lupus Nephritis
Feb 08, 2016: Aurinia Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus Nephritis
Feb 02, 2016: Deltanoid Pharmaceuticals Announces Appointment of Douglas Jermasek as Chief Executive Officer
Jan 19, 2016: Aurinia Announces Completion of Patient Enrollment in Its Phase 2B AURA-LV Study in Lupus Nephritis
Dec 03, 2015: Ocata’s Hemangio-derived Mesenchymal Cells Preserve Kidney Function and Extend Lifespan in Preclinical Model of Lupus Nephritis
Nov 24, 2015: Aurinia Pharmaceuticals Announces Outcome from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis - Study to Continue as Planned
Nov 10, 2015: Kineta, Seattle Children’s Research Institute Present New Data Demonstrating Positive, Predictive Responses to Dalazatide In Lupus
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Lupus Nephritis, H2 2016
Number of Products under Development for Lupus Nephritis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd.1)
Products under Investigation by Universities/Institutes, H2 2016
Lupus Nephritis - Pipeline by AbbVie Inc, H2 2016
Lupus Nephritis - Pipeline by Asahi Kasei Pharma Corp., H2 2016
Lupus Nephritis - Pipeline by Astellas Pharma Inc., H2 2016
Lupus Nephritis - Pipeline by Aurinia Pharmaceuticals Inc, H2 2016
Lupus Nephritis - Pipeline by Azano Pharmaceuticals Inc., H2 2016
Lupus Nephritis - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Lupus Nephritis - Pipeline by Bristol-Myers Squibb Company, H2 2016
Lupus Nephritis - Pipeline by Deltanoid Pharmaceuticals Inc., H2 2016
Lupus Nephritis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Lupus Nephritis - Pipeline by GlaxoSmithKline Plc, H2 2016
Lupus Nephritis - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
Lupus Nephritis - Pipeline by Invion Limited, H2 2016
Lupus Nephritis - Pipeline by KPI Therapeutics, Inc., H2 2016
Lupus Nephritis - Pipeline by MedImmune, LLC, H2 2016
Lupus Nephritis - Pipeline by Omeros Corporation, H2 2016
Lupus Nephritis - Pipeline by Ra Pharmaceuticals, Inc., H2 2016
Lupus Nephritis - Pipeline by Resolve Therapeutics, LLC, H2 2016
Lupus Nephritis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Lupus Nephritis - Pipeline by TxCell SA, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Lupus Nephritis - Dormant Projects, H2 2016
Lupus Nephritis - Dormant Projects (Contd.1), H2 2016
Lupus Nephritis - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Lupus Nephritis, H2 2016
Number of Products under Development for Lupus Nephritis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

AbbVie Inc
Asahi Kasei Pharma Corp.
Astellas Pharma Inc.
Aurinia Pharmaceuticals Inc
Azano Pharmaceuticals Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Deltanoid Pharmaceuticals Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
HanAll Biopharma Co., Ltd.
Invion Limited
KPI Therapeutics, Inc.
MedImmune, LLC
Omeros Corporation
Ra Pharmaceuticals, Inc.
Resolve Therapeutics, LLC
Takeda Pharmaceutical Company Limited
TxCell SA
Skip to top


Lupus Nephritis Global Clinical Trials Review, H1, 2016 US$ 2,125.00 Mar, 2016 · 132 pages
Neovacs SA - Product Pipeline Review - 2015 US$ 1,275.00 Dec, 2015 · 29 pages

Ask Your Question

Lupus Nephritis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: